InSphero

InSphero is the only 3D in vitro model company with the platform and expertise to modernize drug discovery in a way that empowers researchers to reach their full potential. InSphero’s goal is to inspire the next generation of breakthrough therapies through customer centricity, commitment to innovation, and the model of excellence. InSphero is challenging the status quo and working to make 3D in vitro platforms accessible to researchers everywhere. InSphero was founded in 2009 as an official spin-​off from the Swiss Federal Institute of Technology – ETH Zürich. InSphero's Liver Disease team has published a groundbreaking peer-reviewed paper in Nature's Scientific Reports, challenging the limitations of in vitro models in MASH Drug Discovery. We are challenging the status quo, enabling the transition to alternatives to animal testing, and working to make human tissue 3D in vitro models accessible to researchers everywhere. We are the only 3D in vitro technology company providing up to 384 uniform cell culture models in an automation-compatible plate format ready for industry application. As our discovery partner, InSphero gives us immediate access to new 3D cell culture in vitro technologies, such as organ-on-a-chip systems, that provide deep mechanistic insights into complex diseases.